Cannabis Use in Patients With Cancer: A Clinical Review

Abstract

Cannabis use and interest continues to increase among patients with cancer and caregivers. High-quality research remains scant in many areas, causing hesitancy or discomfort among most clinical providers. Although we have limitations on hard outcomes, we can provide some guidance and more proactively engage in conversations with patients and family about cannabis. Several studies support the efficacy of cannabis for various cancer and treatment-related symptoms, such as chemotherapy-induced nausea and cancer pain. Although formulations and dosing guidelines for clinicians do not formally exist at present, attention to tetrahydrocannabinol concentration and understanding of risks with inhalation can reduce risk. Conflicting information exists on the interaction between cannabis and immunotherapy as well as estrogen receptor interactions. Motivational interviewing can help engage in more productive, less stigmatized conversations.

© 2022 by American Society of Clinical Oncology

Conception and design: All authors

Collection and assembly of data: All authors

Manuscript writing: All authors

Final approval of manuscript: All authors

Accountable for all aspects of the work: All authors

AUTHORS' DISCLOSURES OF POTENTIAL CONFLICTS OF INTEREST

Cannabis Use in Patients With Cancer: A Clinical Review

The following represents disclosure information provided by authors of this manuscript. All relationships are considered compensated unless otherwise noted. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this manuscript. For more information about ASCO's conflict of interest policy, please refer to www.asco.org/rwc or ascopubs.org/op/authors/author-center.

Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments).

Brooke Worster

Consulting or Advisory Role: Ethos Cannabis (Inst), PAX Therapeutics

Research Funding: Ethos Cannabis (Inst)

Emily R. Hajjar

Consulting or Advisory Role: Prime Therapeutics

Research Funding: Ethos Cannabis (Inst)

Nathan Handley

Research Funding: Nektar (Inst)

No other potential conflicts of interest were reported.

留言 (0)

沒有登入
gif